Product Information
XULTOPHY 100 UNIT-3.6 MG/ML PEN is a brand product labeled by Novo Nordisk, priced at $85.8856 per ML under NDC 00169291115. Its NADAC has been published 459 times since Dec 20, 2017.
Strength
100; 3.6 [iU]/mL; mg/mL
Manufacturer
Novo NordiskNDC
00169291115
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
INSULIN DEGLUDEC; LIRAGLUTIDEApproval Type
Biologic (BLA)
FDA Application
BLA208583On Market Since
11/21/2016
Pharmacological Classes
Price Statistics
The NADAC for XULTOPHY 100 UNIT-3.6 MG/ML PEN has been published 459 times since Dec 20, 2017, and over the history we have for it it has risen 39.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $85.8856 per ML |
|---|---|
| All-time high | $85.9092 (Jun 10, 2026) |
| All-time low | $61.3902 (Dec 20, 2017) |
| 52-week high | $85.9092 |
| 52-week low | $85.8113 |
| Median price | $75.6902 |
| Average price | $75.5185 |
| Largest weekly change | +5.0% (Jan 11, 2023) |
| Weeks tracked | 459 |
| Tracking since | Dec 20, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the insulin degludec and liraglutide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novo Nordisk manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
insulin degludec and liraglutide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
GLP-1 Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XULTOPHY 100 UNIT-3.6 MG/ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for XULTOPHY 100 UNIT-3.6 MG/ML PEN, manufactured by Novo Nordisk, is $85.8856 per ML (NDC 00169291115), effective Sep 30, 2026.
How has the price of XULTOPHY 100 UNIT-3.6 MG/ML PEN changed over time?
Over the history we have for it, the NADAC for XULTOPHY 100 UNIT-3.6 MG/ML PEN has risen 39.9%. It has been tracked across 459 weekly CMS publications since Dec 20, 2017.
What are the highest and lowest recorded NADAC prices for XULTOPHY 100 UNIT-3.6 MG/ML PEN?
Since Dec 20, 2017, the NADAC for XULTOPHY 100 UNIT-3.6 MG/ML PEN has ranged from a low of $61.3902 (Dec 20, 2017) to a high of $85.9092 (Jun 10, 2026), with a median of $75.6902 per ML.
Are there cheaper alternatives to XULTOPHY 100 UNIT-3.6 MG/ML PEN?
No other NADAC-published product currently shares the active ingredient and strength of XULTOPHY 100 UNIT-3.6 MG/ML PEN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XULTOPHY 100 UNIT-3.6 MG/ML PEN?
XULTOPHY 100 UNIT-3.6 MG/ML PEN (NDC 00169291115) is labeled by Novo Nordisk, and CMS classifies it as a brand product.